GlaxoSmithKline Overview

  • Founded
  • 2000

Founded
  • Status
  • Public

  • Employees
  • 90,083

Employees
  • Stock Symbol
  • GSK

Stock Symbol
  • Investments
  • 131

  • Share Price
  • $16.86

  • (As of Friday Closing)

GlaxoSmithKline General Information

Description

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Contact Information

Website
www.gsk.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
LON
Primary Office
  • 980 Great West Road
  • GSK House
  • Brentford TW8 9GS
  • England, United Kingdom
+44 020 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

GlaxoSmithKline Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.86 $16.66 $14.08 - $33.35 $67.7B 4.07B 9.6M $4.35

GlaxoSmithKline Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 85,805,042 147,255,446 130,639,794 159,334,602
Revenue 49,073,223 46,911,441 43,710,502 43,065,107
EBITDA 12,437,449 11,784,928 13,005,858 11,948,354
Net Income 17,506,638 6,029,978 7,369,474 5,926,332
Total Assets 67,351,200 106,760,331 109,613,367 104,489,432
Total Debt 24,695,701 32,624,774 37,000,695 40,001,049
Public Fundamental Data provided by Morningstar, Inc. disclaimer

GlaxoSmithKline Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore GlaxoSmithKline‘s full profile, request access.

Request a free trial

GlaxoSmithKline Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might acros
Pharmaceuticals
Brentford, United Kingdom
90,083 As of 2021
000000000

00000

rem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et
000000000000000
Rahway, NJ
00000 As of 0000
00000000

000000

bore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi
000000000000000
Cambridge, United Kingdom
00000 As of 0000
00.000
00000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

GlaxoSmithKline Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Merck & Co. Corporation Rahway, NJ 00000 00000000
00000000000 Formerly PE-Backed Cambridge, United Kingdom 00000 00.000 00000000 00.000
00000000 Corporation Basel, Switzerland 000000 000000000000
000000 Corporation New York, NY 00000 000000000-00
00000000 000000000 Corporation Gaithersburg, MD 0000 00000 000000000 00000
You’re viewing 5 of 16 competitors. Get the full list »

GlaxoSmithKline Patents

GlaxoSmithKline Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-202208779-D0 Combined therapy Pending 15-Jun-2022
GB-202208339-D0 Saponin production Pending 07-Jun-2022
GB-202208089-D0 Immunogenic composition Pending 01-Jun-2022
GB-202208093-D0 Immunogenic composition Pending 01-Jun-2022
GB-202205833-D0 Bacteriophage Pending 21-Apr-2022
To view GlaxoSmithKline’s complete patent history, request access »

GlaxoSmithKline Executive Team (119)

Name Title Board Seat Contact Info
Dame Emma Walmsley Chief Executive Officer & Board Director
Emma Walmsley Chief Executive Officer & Board Member
John Clarke President, Consumer Healthcare
David Redfern President, Corporate Development
Iain Mackay Chief Financial Officer & Board Member
You’re viewing 5 of 119 executive team members. Get the full list »

GlaxoSmithKline Board Members (29)

Name Representing Role Since
0000 0000 00 Self Board Member 000 0000
0000000 00000000 GlaxoSmithKline Board Member 000 0000
0000 0000 00000000 GlaxoSmithKline Chief Executive Officer & Board Director 000 0000
0000 00000000 GlaxoSmithKline Chief Executive Officer & Board Member 000 0000
000 000000 00 GlaxoSmithKline Chief Scientific Officer, President of Research & Development, Board Member & Executive Director 000 0000
You’re viewing 5 of 29 board members. Get the full list »

GlaxoSmithKline Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

GlaxoSmithKline Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore GlaxoSmithKline‘s full profile, request access.

Request a free trial

GlaxoSmithKline Investments & Acquisitions (131)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 22-Sep-2022 0000 000 Biotechnology 0000 0000
000000000 15-Aug-2022 0000000000 000 Drug Discovery 000 00000
000000 000000 30-Jun-2022 0000000000 00.00 Drug Discovery 0000 0000
00000000 23-Mar-2022 00000 0000 00000 Drug Discovery
Ophidia 30-Mar-2021 Grant 000.00 Other Healthcare Technology Systems
You’re viewing 5 of 131 investments and acquisitions. Get the full list »

GlaxoSmithKline Subsidiaries (9)

Company Name Industry Location Founded
Affinivax Drug Discovery Cambridge, MA 2014
000000 000000000 0 Corporate Venture Capital Cambridge, MA 0000
00000 00 0000000 0 Corporate Pension Rixensart, Belgium 0000
00 000 Venture Capital Wayne, PA 0000
000000000000000 00 Corporate Pension Philadelphia, PA 0000
You’re viewing 5 of 9 subsidiaries. Get the full list »

GlaxoSmithKline Exits (57)

Company Name Exit Date Exit Type Exit Size Status Buyers
000000 00000000000 03-Aug-2020 0000 0000 Completed
  • 000000000000000
00000000000 000000 29-Mar-2019 00000 00000 00 00000 Completed
  • 15 buyers
000000000 00000000 14-Sep-2018 000 00000 Completed
  • 000000000000000
0000000 23-Jul-2018 00000 00000 00 00000 Completed
  • 6 buyers
Joint Venture (GlaxoSmithKline / Novartis) 01-Jun-2018 Secondary Transaction - Private 0000 Completed
You’re viewing 5 of 57 exits. Get the full list »